German biotech firm MorphoSys on Friday announced a cross licence agreement with Eli Lilly (LLY.N: Quote, Profile, Research) as part of a settlement to resolve patent litigation initiated by an Eli Lilly subsidiary. The financial terms were not disclosed. Shares of MorphoSys jumped more than 5 percent and were at 36.50 euros soon after the markets opened. The TecDax index was flat. Under the terms of the agreement, which lasts four years, Eli Lilly will have access to the MorphoSys research library, which is used by researchers worldwide for human antibody generation.